Psoriasis products
Executive Summary
FDA's Dermatologic & Ophthalmic Drugs Advisory Committee will discuss clinical design questions for psoriasis products on Oct. 21. The committee will also meet on Oct. 22 to consider clinical design issues for systemic immunomodulatory biological products for psoriasis. The meeting will be held at the Gaithersburg, Md. Holiday Inn beginning at 8 a.m. both days